Novo Nordisk A/S (NOV.DE)

EUR 103.14

(-0.33%)

Net Debt Summary of Novo Nordisk A/S

  • Novo Nordisk A/S's latest annual net debt in 2023 was 1.69 Billion DKK , down -3.92% from previous year.
  • Novo Nordisk A/S's latest quarterly net debt in 2024 Q1 was 2.75 Billion DKK , up 63.34% from previous quarter.
  • Novo Nordisk A/S reported annual net debt of 1.76 Billion DKK in 2022, down -17.78% from previous year.
  • Novo Nordisk A/S reported annual net debt of 2.14 Billion DKK in 2021, up 763.84% from previous year.
  • Novo Nordisk A/S reported quarterly net debt of 2.75 Billion DKK for 2024 Q1, up 63.34% from previous quarter.
  • Novo Nordisk A/S reported quarterly net debt of 1.69 Billion DKK for 2023 FY, down -3.92% from previous quarter.

Annual Net Debt Chart of Novo Nordisk A/S (2023 - 2016)

Historical Annual Net Debt of Novo Nordisk A/S (2023 - 2016)

Year Net Debt Net Debt Growth
2023 1.69 Billion DKK -3.92%
2022 1.76 Billion DKK -17.78%
2021 2.14 Billion DKK 763.84%
2020 -322.56 Million DKK 78.07%
2019 -1.47 Billion EUR 27.41%
2018 -2.02 Billion EUR 12.06%
2017 -2.3 Billion EUR 7.18%
2016 -2.48 Billion EUR 0.0%

Peer Net Debt Comparison of Novo Nordisk A/S

Name Net Debt Net Debt Difference
BioNTech SE -11.44 Billion EUR 114.781%
CureVac N.V. -360.92 Million EUR 568.703%
Biotest Aktiengesellschaft 571.3 Million EUR -196.109%
Biotest Aktiengesellschaft 571.3 Million EUR -196.109%
BRAIN Biotech AG -693 Thousand EUR 244208.0%
Formycon AG 2.45 Million EUR -68919.52%
Heidelberg Pharma AG -37.6 Million EUR 4598.216%
Medigene AG -5.72 Million EUR 29653.956%